BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 33179838)

  • 1. Pain in survivors of Ewing sarcoma: Prevalence, associated factors and prediction of recurrence.
    Heinemann M; Hoffmann C; Hardes J; Guder W; Streitbürger A; Götte M; Welz TL; Jürgens H; Ranft A; Vieth V; Weckesser M; Schäfers M; Stegger L; Dirksen U
    Pediatr Blood Cancer; 2021 Mar; 68(3):e28801. PubMed ID: 33179838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCMCIE94: an intensified pilot treatment protocol known to be associated with cure in CD 56-negative non-pelvic isolated Ewing sarcoma (EWS) is also associated with no early relapses in non-metastatic extremity EWS.
    Cohen IJ; Toledano H; Stein J; Kollender Y; Fenig E; Konen O; Bar-Sever Z; Issakov J; Feinmesser M; Avigad S; Ash S
    Cancer Chemother Pharmacol; 2019 May; 83(5):859-866. PubMed ID: 30770960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide and carbo-or cisplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study.
    van Maldegem AM; Benson C; Rutkowski P; Blay JY; van den Berg H; Placzke J; Rasper M; Judson I; Juergens H; Dirksen U; Gelderblom H
    Pediatr Blood Cancer; 2015 Jan; 62(1):40-4. PubMed ID: 25251256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model: A multistate model for Ewing sarcoma.
    Bosma SE; Rueten-Budde AJ; Lancia C; Ranft A; Dirksen U; Krol AD; Gelderblom H; van de Sande MAJ; Dijkstra PDS; Fiocco M
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27943. PubMed ID: 31389188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma.
    Lin PP; Jaffe N; Herzog CE; Costelloe CM; Deavers MT; Kelly JS; Patel SR; Madewell JE; Lewis VO; Cannon CP; Benjamin RS; Yasko AW
    Cancer; 2007 Feb; 109(3):603-11. PubMed ID: 17177205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrence of Ewing sarcoma: Is detection by imaging follow-up protocol associated with survival advantage?
    Heinemann M; Ranft A; Langer T; Jürgens H; Kreyer J; Vieth V; Schäfers M; Weckesser M; Simon T; Hassenpflug W; Corbacioglu S; Bielack S; Mayer-Steinacker R; Kühne T; van den Berg H; Gelderblom H; Bauer S; Stegger L; Dirksen U
    Pediatr Blood Cancer; 2018 Jul; 65(7):e27011. PubMed ID: 29480574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).
    Longhi A; Ferrari S; Tamburini A; Luksch R; Fagioli F; Bacci G; Ferrari C
    Cancer; 2012 Oct; 118(20):5050-9. PubMed ID: 22415578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors.
    Kebudi R; Cakir FB; Gorgun O; Agaoglu FY; Darendeliler E
    Pediatr Hematol Oncol; 2013 Apr; 30(3):170-7. PubMed ID: 23484903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pelvic Ewing sarcoma: a retrospective analysis of 241 cases.
    Hoffmann C; Ahrens S; Dunst J; Hillmann A; Winkelmann W; Craft A; Göbel U; Rübe C; Voute PA; Harms D; Jürgens H
    Cancer; 1999 Feb; 85(4):869-77. PubMed ID: 10091764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-relapse survival in patients with Ewing sarcoma.
    Ferrari S; Luksch R; Hall KS; Fagioli F; Prete A; Tamburini A; Tienghi A; DiGirolamo S; Paioli A; Abate ME; Podda M; Cammelli S; Eriksson M; Brach del Prever A
    Pediatr Blood Cancer; 2015 Jun; 62(6):994-9. PubMed ID: 25585917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of extraskeletal vs. skeletal Ewing sarcoma patients treated with standard chemotherapy protocol.
    Salah S; Abuhijla F; Ismail T; Yaser S; Sultan I; Halalsheh H; Shehadeh A; Abdelal S; Almousa A; Jaber O; Abu-Hijlih R
    Clin Transl Oncol; 2020 Jun; 22(6):878-883. PubMed ID: 31429039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection.
    Pan HY; Morani A; Wang WL; Hess KR; Paulino AC; Ludwig JA; Lin PP; Daw NC; Mahajan A
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):349-57. PubMed ID: 25772182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution and Surgical Management of Visceral Ewing Sarcoma Among Children and Adolescents.
    Wallace MW; Niec JA; Ghani MOA; McKay KG; Idrees K; Liang J; Borinstein SC; Lovvorn HN
    J Pediatr Surg; 2023 Sep; 58(9):1727-1735. PubMed ID: 36774201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of chemotherapy cycles and intervals on outcomes of nonspinal Ewing sarcoma in adults: a real-world experience.
    Zhang J; Huang Y; Sun Y; He A; Zhou Y; Hu H; Yao Y; Shen Z
    BMC Cancer; 2019 Dec; 19(1):1168. PubMed ID: 31791278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999.
    Bacci G; Longhi A; Barbieri E; Ferrari S; Mercuri M; Briccoli A; Versari M; Pignotti E; Picci P
    J Pediatr Hematol Oncol; 2005 Oct; 27(10):517-20. PubMed ID: 16217253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.
    Thiel U; Wawer A; von Luettichau I; Bender HU; Blaeschke F; Grunewald TG; Steinborn M; Röper B; Bonig H; Klingebiel T; Bader P; Koscielniak E; Paulussen M; Dirksen U; Juergens H; Kolb HJ; Burdach SE
    Oncotarget; 2016 Oct; 7(43):70959-70968. PubMed ID: 27486822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pelvis Ewing sarcoma: Local control and survival in the modern era.
    Ahmed SK; Robinson SI; Arndt CAS; Petersen IA; Haddock MG; Rose PS; Issa Laack NN
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28244685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes with nondose-dense chemotherapy for Ewing sarcoma: A practical approach for the developing world.
    Parambil BC; Vora T; Sankaran H; Prasad M; Bakshi A; Puri A; Gulia A; Qureshi S; Laskar S; Khanna N; Shah S; Ramadwar M; Kembhavi S; Chinnaswamy G; Banavali S
    Pediatr Blood Cancer; 2020 Nov; 67(11):e28604. PubMed ID: 32706522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy.
    Choy E; Butrynski JE; Harmon DC; Morgan JA; George S; Wagner AJ; D'Adamo D; Cote GM; Flamand Y; Benes CH; Haber DA; Baselga JM; Demetri GD
    BMC Cancer; 2014 Nov; 14():813. PubMed ID: 25374341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult Ewing sarcoma: survival and local control outcomes in 36 patients with metastatic disease.
    Ahmed SK; Robinson SI; Okuno SH; Rose PS; Issa Laack NN
    Am J Clin Oncol; 2014 Oct; 37(5):423-9. PubMed ID: 23388557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.